SCHEMBL8918959

SCHEMBL8918959

FC(F)(F)c1ccccc1CCO[C@H]1CCCCC1N1CCOCC1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 4/20 0.67
SCN5A Q14524 4/20 0.67
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TACR1 P25103 1/20 0.38
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
CYP2D6 P10635 1/20 0.37
KCNH2 Q12809 1/20 0.37
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
CYP2C9 P11712 1/20 0.36
EPHX2 P34913 1/20 0.36
GAA P10253 3/20 0.35
ATM Q13315 2/20 0.35
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12391702 1.00 KCNA5 (0.67) KCNA5SCN5AKDM4EALDH1A1TACR1
SCHEMBL2624926 1.00 KCNA5 (0.67) KCNA5SCN5AKDM4EALDH1A1TACR1
SCHEMBL14436556 1.00 KCNA5 (0.67) KCNA5SCN5AKDM4EALDH1A1TACR1
Hydrochloric Acid SCHEMBL5949068 0.99 KCNA5 (0.66) KCNA5SCN5AKDM4EALDH1A1TACR1
Hydrochloric Acid SCHEMBL1762340 0.99 KCNA5 (0.66) KCNA5SCN5AKDM4EALDH1A1TACR1
Hydrochloric Acid SCHEMBL2953561 0.99 KCNA5 (0.66) KCNA5SCN5AKDM4EALDH1A1TACR1
Hydrochloric Acid SCHEMBL1762321 0.99 KCNA5 (0.66) KCNA5SCN5AKDM4EALDH1A1TACR1
SCHEMBL14434183 0.85 KCNA5 (0.71) KCNA5SCN5ASLC6A4KCNH2
SCHEMBL12810312 0.82 KCNA5 (0.71) KCNA5SCN5ASLC6A4KCNH2
SCHEMBL2624922 0.82 KCNA5 (0.71) KCNA5SCN5AKDM4EALDH1A1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188140-B2 Uses of ion channel modulating compounds CARDIOME PHARMA CORP. 2012-05-29 US disclosed
US-8188140-B2 Uses of ion channel modulating compounds CARDIOME PHARMA CORP. 2012-05-29 US disclosed
US-20110118329-A1 USES OF ION CHANNEL MODULATING COMPOUNDS CARDIOME PHARMA CORP. (CA) 2011-05-19 US disclosed
US-20110118329-A1 USES OF ION CHANNEL MODULATING COMPOUNDS CARDIOME PHARMA CORP. (CA) 2011-05-19 US disclosed
US-20070190156-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070190156-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885KDM4E 2163/4885
US-20110118329-A1 USES OF ION CHANNEL MODULATING COMPOUNDS KCNN1, KCNN2, KCNN3 KCNA5 48/4885SCN5A 49/4885KDM4E 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.